Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysplastic Syndrome (MDS) Receiving Decitabine.

Peter L Greenberg, MD, Guillermo Garcia-Manero, MD, Michael R Moore, MD, Lloyd E. Damon, MD, Gail J. Roboz, MD, Helen Wei, Hagop Kantarjian, MD, Janet L. Franklin, MD, MPH

Blood (2009) 114 (22): 1769.

https://doi.org/10.1182/blood.V114.22.1769.1769

Published: 2009

Journal Articles

Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide.

Roger M Lyons, Richard A. Larson, MD, Michael A. Kosmo, MD, Sunil Gandhi, Delong Liu, MD, PhD, Marc Chernoff, Luke Dreisbach, MD, Carmen Matei, Kuolong Hu, PhD, Janet L. Franklin, MD, MPH, Dietmar Berger, MD, PhD

Blood (2009) 114 (22): 1770.

https://doi.org/10.1182/blood.V114.22.1770.1770

Published: 2009

Journal Articles

High Expression of the Very Late Antigen (VLA)-4 (CD49d) Integrin Predicts for Reduced Risk of Relapse and Better Outcome in Pediatric Acute Myeloid Leukemia (AML): A Report From the Children's Oncology Group.

Walter B. Walter, MD, PhD, Todd A. Alonzo, PhD, Robert B. Gerbing, MS, Franklin O. Smith, MD, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Alan S. Gamis, MD, Janet L. Franklin, MD, MPH, Craig A. Hurwitz, MD, Michael R. Loken, PhD, Soheil Meshinchi, MD, PhD

Blood (2009) 114 (22): 1592.

https://doi.org/10.1182/blood.V114.22.1592.1592

Published: 2009

Journal Articles

An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS).

Pierre Fenaux, Hagop Kantarjian, MD, Roger Lyons, Richard A. Larson, MD, Mikkael A. Sekeres, MD, MS, Pamela S. Becker, MD, PhD, Petra Muus, MD, PhD, Kuolong Hu, PhD, Dietmar Berger, MD, PhD, Janet L. Franklin, MD, MPH

Blood (2009) 114 (22): 2765.

https://doi.org/10.1182/blood.V114.22.2765.2765

Published: 2009

Journal Articles

Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML – A Report From the Children's Oncology Group.

Jason N. Berman, MD, Robert B. Gerbing, PhD, Lillian Sung, MD, Kristen Miller, BS, Jessica A. Pollard, MD, Phoenix Ho, Derek Stirewalt, Jerald Radich, MD, Craig A. Hurwitz, MD, Nyla A. Heerema, PhD, Betsy Hirsch, MD, Susana C. Raimondi, PhD, Beverly Lange, MD, Alan S. Gamis, MD, Janet L. Franklin, MD, MPH, Todd A. Alonzo, PhD, Soheil Meshinchi, MD, PhD

Blood (2009) 114 (22): 3115.

https://doi.org/10.1182/blood.V114.22.3115.3115

Published: 2009

Journal Articles

Minimal Residual Disease Detection by Four-Color Multidimensional Flow Cytometry Identifies Pediatric AML Patients at High Risk of Relapse.

Soheil Meshinchi, MD, PhD, Todd Alonzo, PhD, Robert B. Gerbing, MA, Jessica A. Pollard, MD, Alan S. Gamis, MD, MPH, Craig A. Hurwitz, MD, Janet L. Franklin, MD, Laura Pardo, MD, Michael Loken, PhD

Blood (2007) 110 (11): 1429.

https://doi.org/10.1182/blood.V110.11.1429.1429

Published: 2007

Journal Articles

A Phase I Study of Oral 6-Thioguanine, Followed by Continuous Infusion Cytarabine, Followed by Intramuscular PEG-Asparaginase (“TGAP”) in Children with Relapsed or Refractory Acute Leukemia or Non-Hodgkin’s Lymphoma.

Cecilia H. Fu, MD, Janet L. Franklin, MD, Paul Gaynon, MD, Colleen McCarthy, RN, Edward Panosyan, MD, Stuart E. Siegel, MD, Vassilios I. Avramis, MD

Blood (2006) 108 (11): 4536.

https://doi.org/10.1182/blood.V108.11.4536.4536

Published: 2006

NARROW

Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysplastic Syndrome (MDS) Receiving Decitabine.

Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide.

High Expression of the Very Late Antigen (VLA)-4 (CD49d) Integrin Predicts for Reduced Risk of Relapse and Better Outcome in Pediatric Acute Myeloid Leukemia (AML): A Report From the Children's Oncology Group.

An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS).

Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML – A Report From the Children's Oncology Group.

Minimal Residual Disease Detection by Four-Color Multidimensional Flow Cytometry Identifies Pediatric AML Patients at High Risk of Relapse.

A Phase I Study of Oral 6-Thioguanine, Followed by Continuous Infusion Cytarabine, Followed by Intramuscular PEG-Asparaginase (“TGAP”) in Children with Relapsed or Refractory Acute Leukemia or Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysplastic Syndrome (MDS) Receiving Decitabine.

Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide.

High Expression of the Very Late Antigen (VLA)-4 (CD49d) Integrin Predicts for Reduced Risk of Relapse and Better Outcome in Pediatric Acute Myeloid Leukemia (AML): A Report From the Children's Oncology Group.

An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS).

Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML – A Report From the Children's Oncology Group.

Minimal Residual Disease Detection by Four-Color Multidimensional Flow Cytometry Identifies Pediatric AML Patients at High Risk of Relapse.

A Phase I Study of Oral 6-Thioguanine, Followed by Continuous Infusion Cytarabine, Followed by Intramuscular PEG-Asparaginase (“TGAP”) in Children with Relapsed or Refractory Acute Leukemia or Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only